

SUPPORTING INFORMATION

Cytoplasmic dynein antagonists with improved potency and isoform selectivity

Stephanie K. See[†], Sascha Hoogendoorn[†], Andrew H. Chung[†], Fan Ye[‡],
Jonathan B. Steinman^{||}, Tomoyo Sakata-Kato^{†,¶}, Rand M. Miller^{||}, Tommaso Cupido^{||},
Ruta Zalyte[±], Andrew P. Carter[±], Maxence V. Nachury[‡],
Tarun M. Kapoor^{||}, and James K. Chen^{*,†,§}

[†]Department of Chemical and Systems Biology, [‡]Department of Molecular and Cellular Physiology, and [§]Department of Developmental Biology, Stanford University School of Medicine, Stanford, CA 94305, USA

^{||}Laboratory of Chemistry and Cell Biology, Rockefeller University, New York City, NY 10065, USA

[±]Medical Research Council Laboratory of Molecular Biology, Division of Structural Studies, Cambridge CB2 0QH, UK

[¶]Present address: Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115

*Corresponding author. Department of Chemical and Systems Biology, Stanford University School of Medicine, 269 Campus Drive, CCSR 3155, Stanford, CA 94305, USA. Tel: 650-725-3582. Fax: 650-723-2253. Email: jameschen@stanford.edu

TABLE OF CONTENTS

Figure S1	3
Figure S2	4
Figure S3	5
Figure S4	6
Methods and Materials – Synthetic Procedures	7-23
Methods and Materials – Biochemical and Cellular Assays	24-35
References	36-37
¹H NMR Spectra for Ciliobrevin Analogs 1-48	38-85




Figure S1. C7-benzyl ether ciliobrevins reversibly disrupt IFT88 trafficking. IFT88 distributions along the ciliary axoneme in response to treatment with analog **43** for 1 hour and then compound washout for 4 hours. Representative micrographs of an NIH-3T3 cell-derived line are shown with staining for IFT88, ARL13B (primary cilia), γ -tubulin (basal body), and DNA. Scale bar: 2 μ m. Each axoneme was divided into 21 bins, and the IFT88 signal intensity within each bin was normalized to the total ciliary signal using Matlab R2014A (Mathworks). Data represent the average IFT88 signal intensities for 65 cilia \pm s.e.m.




Figure S2. Effects of C7-benzyl ether ciliobrevins on Golgi morphology and GLI2 trafficking. Representative Golgi organization and GLI2 trafficking phenotypes observed in a serum-starved NIH-3T3 cell-derived line treated with DMSO or ciliobrevins for 4 hours. Cytoplasmic dynein 1 inhibition causes Golgi vesicle dispersion, whereas cytoplasmic dynein 2 blockade causes GLI2 accumulation at the distal tip of primary cilia (ARL13B). Scale bar: 5 μm. Quantitative analyses of the Golgi (top) and GLI2 (bottom) phenotypes are shown. GLI2 signal intensities at the ciliary tip were normalized to that of a SAG-treated control. At least 100 cells were scored for each condition, and GLI2 intensities are shown as average values ± s.e.m of three independent experiments..




Figure S3. ATP concentration-dependent inhibition of cytoplasmic dynein 1 and 2 motor domains by ciliobrevins. Dose-dependent inhibition of DYNC1H1 (black) and DYNC2H1 (red) motor ATPase activities by ciliobrevin analog **37** at 25 nM and 100 μM ATP concentrations. Data are the average of triplicate samples ± s.e.m.





Figure S4. Comparison of the nucleotide-binding sites in the cytoplasmic dynein 2 heavy chain. Stereoviews of the nucleotide-binding sites in DYNCH2H1, visualized from their most solvent-accessible faces (PDB ID: ARH7). Space-filling (left) and surface (right) renderings are shown, and the linker region N-terminal to the AAA1 domain has been omitted for clarity. Adenine-interacting residues that are conserved between DYNCH1H1 and DYNCH2H1 are depicted in blue, variable residues in green, and nucleotides in red.

MATERIALS AND METHODS — SYNTHETIC PROCEDURES


Ciliobrevins A (**1**) and D (**2**) and analog **25** were synthesized as previously described.^{1,2} Ciliobrevins **3-19** and **23-31** were prepared using Procedure A, while analogs **20**, **21**, and **22** were obtained through separate routes. Benzyl ether derivatives **32-48** were prepared through Procedure B. Unless otherwise noted, all reactions were performed under a nitrogen atmosphere. THF, DMF, and acetonitrile were distilled from calcium hydride and stored over 4 Å molecular sieves. Other reagents and solvents obtained from commercial sources were used directly without further purification. Purification of products was conducted by flash chromatography on silica gel (EM Science, 70-230 mesh; Sorbtech, 230-400 mesh; or Qingdao Haiyang Chemical, 200-300 mesh). ¹H NMR spectra were recorded on Varian or Bruker NMR spectrometers, and chemical shifts are reported in δ units (ppm) using residual solvent as the internal standard. High-resolution mass spectra were obtained on quadrupole time-of-flight (Q-TOF) mass spectrometers utilizing the electrospray ionization method.

Representative procedure A for the synthesis of ciliobrevins 3-19 and 23-31



2-(4-oxo-3,4-dihydroquinazolin-2-yl)acetonitrile derivatives. 2-cyanothioacetamide (200 mg, 2.00 mmol) and bromoethane (165 μL, 2.21 mmol) were added to an ethanolic solution of sodium ethoxide (2.00 mL, 2.20 mmol). The resulting mixture was stirred for 6 h. The corresponding substituted 2-aminobenzoic acid (2.00 mmol) was added, and the reaction was refluxed overnight with stirring. A solid precipitate formed upon cooling of the reaction mixture,

which was recovered by vacuum filtration and washed sequentially with ethanol, water, ethanol, and diethyl ether. The solid was then dried to yield the substituted 2-(4-oxo-3,4-dihydroquinazolin-2-yl) acetonitrile. Synthetic yields ranged from 30-50%.



3-oxo-2-(4-oxo-3,4-dihydroquinazolin-2(1*H*)-ylidene)-3-phenylpropanenitrile derivatives.

To a solution of 2-(4-oxo-1,4-dihydroquinazolin-2-yl)acetonitrile (92.5 mg, 0.499 mmol) and triethylamine (84 μ L, 0.60 mmol) in dioxane (5 mL) was added the corresponding acyl chloride (0.500 mmol), and the resulting mixture was refluxed overnight with stirring. A solid precipitate formed upon cooling of the reaction mixture, which was recovered by vacuum filtration and washed sequentially with methanol, water, methanol, and dichloromethane. The solid was then dried to yield the desired product. Synthetic yields ranged from 30-70%.

¹H NMR and HRMS data for ciliobrevins 3-19 and 23-31

3-(2,4-dichlorophenyl)-2-(6-methyl-4-oxo-3,4-dihydroquinazolin-2(1*H*)-ylidene)-3-oxopropanenitrile (3). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.55 (br s, 1H), 7.85 (s, 1H), 7.73-7.75 (m, 2H), 7.65 (d, *J* = 8.4 Hz, 1H), 7.48-7.55 (m, 2H), 2.41 (s, 3H). HRMS (*m/z*) calc. for C₁₈H₁₂Cl₂N₃O₂ [M + H]⁺, 372.0307; observed, 372.0288.

3-(2,4-dichlorophenyl)-2-(7-methyl-4-oxo-3,4-dihydroquinazolin-2(1*H*)-ylidene)-3-oxopropanenitrile (4). ¹H NMR (500 MHz, DMSO-*d*₆) δ 13.46 (br s, 1H), 7.94 (d, *J* = 8.0 Hz, 1H),

7.74 (s, 1H), 7.65 (s, 1H), 7.49-7.55 (m, 2H), 7.29 (d, $J = 7.9$ Hz, 1H), 2.44 (s, 3H). HRMS (m/z) calc. for $C_{18}H_{12}Cl_2N_3O_2$ $[M + H]^+$, 372.0307; observed, 372.0305.

3-(2,4-dichlorophenyl)-2-(6-ethyl-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-oxopropanenitrile (5). 1H NMR (400 MHz, DMSO- d_6) δ 13.54 (br s, 1H), 7.87 (s, 1H), 7.70-7.79 (m, 3H), 7.50-7.56 (m, 2H), 2.73 (q, $J = 7.2$ Hz, 2H), 1.22 (t, $J = 7.2$ Hz, 3H). HRMS (m/z) calc. for $C_{19}H_{12}Cl_2N_3O_2$ $[M - H]^-$, 384.0307; observed, 384.0309.

3-(2,4-dichlorophenyl)-2-(7-ethyl-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-oxopropanenitrile (6). 1H NMR (400 MHz, DMSO- d_6) δ 13.42 (br s, 1H), 7.95 (d, $J = 8.0$ Hz, 1H), 7.75 (d, $J = 2.0$ Hz, 1H), 7.71 (s, 1H), 7.49-7.56 (m, 2H), 7.33 (d, $J = 8.4$ Hz, 1H), 2.73 (q, $J = 7.6$ Hz, 2H), 1.22 (t, $J = 7.6$ Hz, 3H). HRMS (m/z) calc. for $C_{19}H_{12}Cl_2N_3O_2$ $[M - H]^-$, 384.0307; observed, 384.0312.

3-(2,4-dichlorophenyl)-2-(6-isopropyl-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-oxopropanenitrile (7). 1H NMR (400 MHz, DMSO- d_6) δ 13.48 (br s, 1H), 7.89 (d, $J = 1.6$ Hz, 1H), 7.77-7.82 (m, 2H), 7.75 (d, $J = 1.6$ Hz, 1H), 7.49-7.56 (m, 2H), 2.49 (m, 1H), 1.24 (d, $J = 6.8$ Hz, 6H). HRMS (m/z) calc. for $C_{20}H_{14}Cl_2N_3O_2$ $[M - H]^-$, 398.0463; observed, 398.0467.

3-(2,4-dichlorophenyl)-2-(7-isopropyl-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-oxopropanenitrile (8). 1H NMR (300 MHz, DMSO- d_6) δ 13.45 (br s, 1H), 7.96 (d, $J = 8.1$ Hz, 1H), 7.77 (d, $J = 1.8$ Hz, 2H), 7.50-7.58 (m, 2H), 7.41 (dd, $J = 1.2, 8.1$ Hz, 1H), 3.01-3.05 (m, 1H),

1.23 (d, $J = 6.9$ Hz, 6H). HRMS (m/z) calc. for $C_{20}H_{14}Cl_2N_3O_2$ $[M - H]^-$, 398.0463; observed, 398.0468.

2-(6-*tert*-butyl-4-oxo-3,4-dihydroquinazolin-2(1*H*)-ylidene)-3-(2,4-dichlorophenyl)-3-oxopropanenitrile (9). 1H NMR (400 MHz, $CDCl_3$) δ 8.22 (d, $J = 2.0$ Hz, 1H), 7.88 (dd, $J = 2.4, 8.4$ Hz, 1H), 7.50 (d, $J = 1.6$ Hz, 1H), 7.35-7.42 (m, 3H), 1.40 (s, 9H). HRMS (m/z) calc. for $C_{21}H_{16}Cl_2N_3O_2$ $[M - H]^-$, 412.0620; observed, 412.0626.

2-(7-*tert*-butyl-4-oxo-3,4-dihydroquinazolin-2(1*H*)-ylidene)-3-(2,4-dichlorophenyl)-3-oxopropanenitrile (10). 1H NMR (400 MHz, $CDCl_3$) δ 8.14 (d, $J = 8.4$ Hz, 1H), 7.50-7.55 (m, 2H), 7.34-7.42 (m, 3H), 1.40 (s, 9H). HRMS (m/z) calc. for $C_{21}H_{16}Cl_2N_3O_2$ $[M - H]^-$, 412.0620; observed, 412.0624.

3-(2,4-dichlorophenyl)-2-(6-methoxy-4-oxo-3,4-dihydroquinazolin-2(1*H*)-ylidene)-3-oxopropanenitrile (11). 1H NMR (400 MHz, $DMSO-d_6$) δ 13.54 (br s, 1H), 7.80 (d, $J = 9.6$ Hz, 1H), 7.75 (s, 1H), 7.46-7.56 (m, 4H), 3.86 (s, 3H). HRMS (m/z) calculated for $C_{18}H_{12}Cl_2N_3O_3$ $[M + H]^+$: 388.0256; observed: 388.0233.

3-(2,4-dichlorophenyl)-2-(7-methoxy-4-oxo-3,4-dihydroquinazolin-2(1*H*)-ylidene)-3-oxopropanenitrile (12). 1H NMR (500 MHz, $DMSO-d_6$) δ 7.97 (d, $J = 9.0$ Hz, 1H), 7.77 (d, $J = 2.0$ Hz, 1H), 7.56 (dd, $J = 8.1, 2.0$ Hz, 1H), 7.52 (d, $J = 8.1$ Hz, 1H), 7.41 (br s, 1H), 7.05 (dd, $J = 9.0, 2.2$ Hz, 1H), 3.89 (s, 3H). HRMS (m/z) calculated for $C_{18}H_{12}Cl_2N_3O_3$ $[M + H]^+$: 388.0256; observed, 388.0241.

3-(2,4-dichlorophenyl)-2-(6-ethoxy-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-oxopropanenitrile (13). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.50 (s, 1H), 7.61 (d, *J* = 2.0 Hz, 1H), 7.34-7.44 (m, 4H), 7.26 (dd, *J* = 2.8, 8.8 Hz, 1H), 4.04 (q, *J* = 7.2 Hz, 2H), 1.35 (t, *J* = 7.2 Hz, 3H). HRMS (*m/z*) calc. for C₁₉H₁₂Cl₂N₃O₃ [M – H][–], 400.0256; observed, 400.0261.

3-(2,4-dichlorophenyl)-2-(7-ethoxy-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-oxopropanenitrile (14). ¹H NMR (400 MHz, CDCl₃) δ 13.33 (br s, 1H), 7.93 (d, *J* = 8.8 Hz, 1H), 7.74 (d, *J* = 2.0 Hz, 1H), 7.49-7.56 (m, 2H), 7.37 (s, 1H), 7.00 (dd, *J* = 2.4, 8.8 Hz, 1H), 4.14 (q, *J* = 7.2 Hz, 2H), 1.38 (t, *J* = 7.2 Hz, 3H). HRMS (*m/z*) calc. for C₁₉H₁₂Cl₂N₃O₃ [M – H][–], 400.0256; observed, 400.0258.

3-(2,4-dichlorophenyl)-3-oxo-2-(4-oxo-6-propoxy-3,4-dihydroquinazolin-2(1H)-ylidene)propanenitrile (15). ¹H NMR (300 MHz, DMSO-*d*₆) δ 13.54 (br s, 1H), 7.76-7.82 (m, 2H), 7.45-7.57 (m, 4H), 4.04 (t, *J* = 6.6 Hz, 2H), 1.73-1.80 (m, 2H), 0.99 (t, *J* = 7.2 Hz, 2H). HRMS (*m/z*) calc. for C₂₀H₁₄Cl₂N₃O₃ [M – H][–], 414.0412; observed, 414.0416.

3-(2,4-dichlorophenyl)-3-oxo-2-(4-oxo-7-propoxy-3,4-dihydroquinazolin-2(1H)-ylidene)propanenitrile (16). ¹H NMR (300 MHz, DMSO-*d*₆) δ 13.37 (br s, 1H), 7.93 (d, *J* = 9.0 Hz, 1H), 7.77 (s, 1H), 7.50-7.57 (m, 2H), 7.40 (s, 1H), 7.01 (d, *J* = 8.7 Hz, 1H), 4.04 (d, *J* = 6.6 Hz, 2H), 1.75-1.82 (m, 2H), 0.99 (t, *J* = 7.2 Hz, 3H). HRMS (*m/z*) calc. for C₂₀H₁₄Cl₂N₃O₃ [M – H][–], 414.0412; observed, 414.0420.

3-(2,4-dichlorophenyl)-2-(6-isopropoxy-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-oxopropanenitrile (17). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.43 (br s, 1H), 7.82 (d, *J* = 9.6 Hz, 1H), 7.75 (s, 1H), 7.69 (s, 1H), 7.49-7.56 (m, 2H), 7.44 (s, 2H), 4.74 (m, 1H), 1.29 (d, *J* = 5.6 Hz, 6H). HRMS (*m/z*) calc. for C₂₀H₁₄Cl₂N₃O₃ [M – H][–], 414.0412; observed, 414.0416.

3-(2,4-dichlorophenyl)-2-(7-isopropoxy-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-oxopropanenitrile (18). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.33 (br s, 1H), 7.92 (d, *J* = 9.2 Hz, 1H), 7.76 (d, *J* = 2.0 Hz, 1H), 7.50-7.57 (m, 2H), 7.40 (d, *J* = 1.6 Hz, 1H), 6.98 (dd, *J* = 2.4, 8.0 Hz, 1H), 4.71 (m, 1H), 1.34 (d, *J* = 6.0 Hz, 6H). HRMS (*m/z*) calc. for C₂₀H₁₄Cl₂N₃O₃ [M – H][–], 414.0412; observed, 414.0420.

(3-(2,4-dichlorophenyl)-2-(6-(dimethylamino)-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-oxopropanenitrile (19). ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.76-7.56 (m, 2H), 7.52 (q, *J* = 1.6, 8.2, 9.9 Hz, 2H), 7.35 (dd, *J* = 2.8, 9.3 Hz, 1H), 7.14 (d, *J* = 2.7 Hz, 1H), 3.00 (s, 3H). HRMS (*m/z*) calc. for C₁₉H₁₅Cl₂N₄O₂ [M + H]⁺, 401.0567; observed, 401.0535.

3-(3,4-dichlorophenyl)-3-oxo-2-(4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)propanenitrile (23). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.07 (d, *J* = 7.8 Hz, 1H), 7.92 (d, *J* = 2.0 Hz, 1H), 7.89 (t, *J* = 7.8 Hz, 1H), 7.86 (t, *J* = 8.3 Hz, 1H), 7.81 (d, *J* = 8.3 Hz, 1H), 7.70 (dd, *J* = 2.0, 8.3 Hz, 1H), 7.48 (t, *J* = 7.8 Hz, 1H). HRMS (*m/z*) calc. for C₁₇H₁₀Cl₂N₃O₂ [M + H]⁺, 358.0145; observed, 358.0133.

3-(3-methoxyphenyl)-3-oxo-2-(4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)propanenitrile

(24). ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.03 (d, *J* = 7.6 Hz, 1H), 7.87 (d, *J* = 8.0 Hz, 1H), 7.80 (t, *J* = 8.0 Hz, 1H), 7.45 (t, *J* = 8.0 Hz, 1H), 7.39 (d, *J* = 8.0 Hz, 1H), 7.27 (d, *J* = 7.6 Hz, 1H), 7.22 (s, 1H), 7.12 (dd, *J* = 1.6, 8.0 Hz, 1H), 3.80 (s, 3H). HRMS (*m/z*) calc. for C₁₈H₁₄N₃O₃ [M + H]⁺, 320.1035; observed, 320.1029.

3-oxo-2-(4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-(pyridin-3-yl)propanenitrile (26).

¹H NMR (400 MHz, DMSO-*d*₆) δ 9.02 (s, 1H), 8.85 (d, *J* = 4.0 Hz, 1H), 8.38 (d, *J* = 8.0 Hz, 1H), 8.05 (d, *J* = 7.6 Hz, 1H), 7.79-7.91 (m, 3H), 7.48 (t, *J* = 7.6 Hz, 1H). HRMS (*m/z*) calc. for C₁₆H₁₁N₄O₂ [M + H]⁺, 291.0882; observed, 291.0865.

3-(2,4-dichlorophenyl)-3-oxo-2-(4-oxo-3,4-dihydrobenzo[*g*]quinazolin-2(1H)-ylidene)propanenitrile (27).

¹H NMR (400 MHz, DMSO-*d*₆) δ 13.42 (br s, 1H), 8.79 (s, 1H), 8.28 (s, 1H), 8.20 (d, *J* = 8.0 Hz, 1H), 8.02 (d, *J* = 8.4 Hz, 1H), 7.76 (s, 1H), 7.71 (t, *J* = 8.0 Hz, 1H), 7.51-7.61 (m, 3H). HRMS (*m/z*) calc. for C₂₁H₁₂Cl₂N₃O₂ [M + H]⁺, 408.0307; observed, 408.0318.

(3-(2,4-dichlorophenyl)-3-oxo-2-(4-oxo-3,4,6,7,8,9-hexahydrobenzo[*g*]quinazolin-2(1H)-ylidene)propanenitrile (28).

¹H NMR (400 MHz, CDCl₃) δ 7.93 (s, 1H), 7.49 (s, 1H), 7.30-7.40 (m, 2H), 7.12 (s, 1H), 2.85-2.96-4.40 (m, 4H), 1.85-1.94 (m, 4H). HRMS (*m/z*) calc. for C₂₁H₁₄Cl₂N₃O₂ [M - H]⁻, 410.0463; observed, 410.0469.

3-(2,4-dichlorophenyl)-3-oxo-2-(4-oxo-3,4,7,8-tetrahydro-[1,4]dioxino[2,3-*g*]quinazolin-

2(1H)-ylidene)propanenitrile (29). ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.74 (d, *J* = 2.0 Hz, 1H),

7.53 (d, $J=8.0$ Hz, 1H), 7.48 (d, $J=8.0$ Hz, 1H), 7.43 (s, 1H), 7.34 (s, 1H), 4.33-4.40 (m, 4H).

HRMS (m/z) calc. for $C_{19}H_{10}Cl_2N_3O_4$ $[M - H]^-$, 414.0048; observed, 414.0054.


3-(2,4-dichlorophenyl)-3-oxo-2-(4-oxo-3,4,7,8-tetrahydro-1H-cyclopenta[g]quinazolin-

2(6H)-ylidene)propanenitrile (30). 1H NMR (400 MHz, $DMSO-d_6$) δ 13.44 (br s, 1H), 7.88 (s, 1H), 7.75 (d, $J=1.6$ Hz, 1H), 7.69 (s, 1H), 7.49-7.56 (m, 2H), 2.96 (m, 4H), 2.06 (t, $J=7.6$ Hz, 2H). HRMS (m/z) calc. for $C_{20}H_{12}Cl_2N_3O_2$ $[M - H]^-$, 396.0307; observed, 396.0305.

3-(2,4-dichlorophenyl)-3-oxo-2-(4-oxo-3,4-dihydrofuro[3,4-g]quinazolin-2(1H,6H,8H)-

ylidene)propanenitrile (31). 1H NMR (300 MHz, $DMSO-d_6$) δ 13.55 (br s, 1H), 8.00 (s, 1H), 7.75-7.77 (m, 2H), 7.52-7.55 (m, 2H), 5.09 (s, 2H), 5.06 (s, 2H). HRMS (m/z) calc. for $C_{19}H_{10}Cl_2N_3O_3$ $[M - H]^-$, 398.0099; observed, 398.0102.


Synthesis of ciliobrevin 20




3-(2,4-dichlorophenyl)-2-(3-methyl-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-oxopropanenitrile (20). To a solution of ciliobrevin A (1) (107 mg, 0.299 mmol) in DMF (2 mL) was added sodium hydride (8.6 mg, 0.36 mmol) at 0 °C, and the reaction mixture was stirred at room temperature for 40 min. To this solution was added iodomethane (47 mg, 0.33 mmol), and the resulting mixture was stirred at room temperature for 3 h. The reaction was quenched by addition of a saturated solution of $NaHCO_3$ (5 mL), and extracted with CH_2Cl_2 (3 \times 20 mL). The

combined organic layers were washed with H₂O and brine, then dried over Na₂SO₄. The solvent was removed *in vacuo* and the residue was directly purified through preparative TLC to give the desired product (26 mg, 23%). ¹H NMR (400 MHz, CDCl₃) δ 15.71 (s, 1H), 8.26 (d, *J* = 8.0 Hz, 1H), 7.78 (dd, *J* = 1.6, 8.0 Hz, 1H), 7.34-7.49 (m, 5H), 3.97 (s, 1H). HRMS (*m/z*) calc. for C₁₈H₁₂Cl₂N₃O₂ [M + H]⁺, 372.0307; observed, 372.0290.

Synthesis of ciliobrevin 21




2-(2,4-dichlorobenzoyl)-3,3-bis(methylthio)acrylonitrile. To a stirred solution of 3-(2,4-dichlorophenyl)-3-oxopropanenitrile (1.06 g, 4.95 mmol) in THF (15 mL) at 0 °C was added dry sodium hydride (0.24 g, 10 mmol). The suspension was stirred at 0 °C for 1 h, at which point carbon disulfide (0.403 g, 5.29 mmol) was added, and the reaction was then stirred at room temperature for another 2 h. The resulting red solution was cooled to 0 °C, iodomethane (1.56 g, 11.0 mmol) was added, and the mixture was stirred at room temperature for 18 h. The solvent was then removed *in vacuo*, and the residue was diluted in ether and washed with brine. The aqueous layer was extracted twice with ether, and the combined organic layers were washed twice with 5% sodium thiosulfate, and then brine. The organic layers were dried over MgSO₄, filtered and concentrated to give the desired acrylonitrile as a yellow powder (1.08 g, 68%). This product was used in the next step without further purification or characterization.



3-(2,4-dichlorophenyl)-2-(3,4-dihydroquinazolin-2(1H)-ylidene)-3-oxopropanenitrile (21).


A solution of 2-(2,4-dichlorobenzoyl)-3,3-bis(methylthio)acrylonitrile (0.954 g, 3.00 mmol) and 2-aminobenzylamine (366 mg, 3.00 mmol) in ethanol (10 mL) was heated to reflux for 4 h. After cooling the precipitate was filtered. Recrystallization from ethanol gave the desired product (380 mg, 37%). $^1\text{H NMR}$ (400 MHz, $\text{DMSO-}d_6$) δ 11.06 (br s, 1H), 9.58 (br s, 1H), 7.69 (s, 1H), 7.50 (dd, $J = 1.6, 8.4$ Hz, 1H), 7.43 (d, $J = 8.4$ Hz, 1H), 7.09-7.24 (m, 4H), 4.59 (s, 2H). HRMS (m/z) calc. for $\text{C}_{17}\text{H}_{12}\text{Cl}_2\text{N}_3\text{O}$ $[\text{M} + \text{H}]^+$, 344.0357; observed, 344.0344.

Synthesis of ciliobrevin 22




1-(2,4-dichlorophenyl)-2-methyl-3,3-bis(methylthio)prop-2-en-1-one. To a stirred solution of 1-(2,4-dichlorophenyl)propan-1-one (1.02 g, 5.02 mmol) in THF (15 ml) at 0 °C was added dry sodium hydride (0.24 g, 10 mmol). The suspension was stirred at 0 °C for 1 h, at which point carbon disulfide (0.403 g, 5.29 mmol) was added, and the reaction was then stirred at room temperature for another 2 h. The resulting red solution was cooled to 0 °C and iodomethane (1.56 g, 11.0 mmol) was added, and the mixture was stirred at room temperature for 18 h. The solvent was then removed *in vacuo*, and the residue was diluted in ether and washed with brine. The aqueous layer was extracted twice with ether, and the combined organic layers were washed

twice with 5% sodium thiosulfate, and then brine. The organic layers were dried over MgSO_4 , filtered and concentrated to give the desired propenone, which was used in the next step without further purification or characterization.




2-(1-(2,4-dichlorophenyl)-1-oxopropan-2-ylidene)-2,3-dihydroquinazolin-4(1H)-one (22). A solution of 1-(2,4-dichlorophenyl)-2-methyl-3,3-bis(methylthio) prop-2-en-1-one (307 mg, 1.00 mol) and 2-aminobenzamide (136 mg, 1.00 mmol) in xylene (10 mL) was heated to reflux for 3 h. After cooling, the precipitate was filtered. Recrystallization from ethanol gave the desired quinazolinone as colorless crystals (118 mg, 34%). ^1H NMR (400 MHz, CDCl_3) δ 15.65 (s, 1H), 8.44 (s, 1H), 8.15 (d, $J = 8.0$ Hz, 1H), 7.70 (dt, $J = 1.6, 8.0$ Hz, 1H), 7.46 (d, $J = 2.0$ Hz, 1H), 7.23-7.35 (m, 4H), 1.80 (s, 3H). HRMS (m/z) calc. for $\text{C}_{17}\text{H}_{13}\text{Cl}_2\text{N}_2\text{O}_2$ $[\text{M} + \text{H}]^+$, 347.0354; observed, 347.0351.

Representative procedure B for the synthesis of ciliobrevins 32-48



3-(2,4-dichlorophenyl)-2-(7-hydroxy-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-oxopropanenitrile. To a solution of ciliobrevin **12** (104 mg, 0.268 mmol) in dry CH_2Cl_2 (15 mL) was

added 1.0 M BBr₃ in CH₂Cl₂ (2.6 mL, 2.6 mmol) at 0 °C. The reaction was allowed to warm to room temperature, continuously stirred for 7 days, and then quenched with water (100 mL). The mixture was then extracted with ethyl acetate (3 x 100 mL), and the organic layers were pooled, washed with brine, and concentrated *in vacuo*. The residue was then purified by silica gel chromatography (CHCl₃/MeOH/triethylamine, 8:1:1). Product containing fractions were combined and sequentially washed with 1N HCl, saturated NaHCO₃, and brine. Drying over MgSO₄ and removal of solvent *in vacuo* yielded the desired hydroxyquinazolinone (79.3 mg, 82%). ¹H NMR (500 MHz, CD₃OD) δ 6.88 (d, *J* = 8.8 Hz, 1H), 6.99 (s, 1H), 7.45 (m, 2H), 7.56 (d, *J* = 1.7 Hz, 1H), 8.00 (d, *J* = 8.3 Hz, 1H). HRMS (*m/z*) calc. for C₁₇H₁₀Cl₂N₃O₃ [M + H]⁺, 374.0099; observed, 374.0087.



2-(7-(benzyloxy)-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-(2,4-dichlorophenyl)-3-oxopropanenitrile derivatives. To a solution of 3-(2,4-dichlorophenyl)-2-(7-hydroxy-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-oxopropanenitrile (37 mg, 0.099 mmol) in DMF (4 mL) was added corresponding benzyl bromide (0.15 mmol) and K₂CO₃ (41 mg, 0.30 mmol), and the reaction was heated at 80 °C overnight with stirring. The mixture was then concentrated *in vacuo*, and the resulting residue was purified through flash chromatography (CH₂Cl₂/MeOH, 30:1) to afford the desired product. Synthetic yields ranged from 40-60%.

¹H NMR and HRMS data for ciliobrevins 32-48

2-(7-(2-chlorobenzyloxy)-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-(2,4-dichlorophenyl)-3-oxopropanenitrile (32). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.42 (br s, 1H), 8.01 (d, *J* = 0.8 Hz, 1H), 7.75-7.43 (m, 8H), 7.16 (m, 1H), 5.30 (s, 2H). HRMS (*m/z*) calc. for C₂₄H₁₄Cl₃N₃O₃ [M – H][–], 496.0022; observed, 496.0027.

2-(7-(3-chlorobenzyloxy)-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-(2,4-dichlorophenyl)-3-oxopropanenitrile (33). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.36 (br s, 1H), 8.00 (d, *J* = 8.8 Hz, 1H), 7.76 (d, *J* = 1.6 Hz, 1H), 7.56-7.45 (m, 7H), 7.15 (dd, *J* = 2.0, 8.8 Hz, 1H), 5.26 (s, 2H). HRMS (*m/z*) calc. for C₂₄H₁₄Cl₃N₃O₃ [M – H][–], 496.0022; observed, 496.0023.

2-(7-(4-chlorobenzyloxy)-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-(2,4-dichlorophenyl)-3-oxopropanenitrile (34). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.33 (br s, 1H), 7.99 (d, *J* = 9.2 Hz, 1H), 7.76 (d, *J* = 1.6 Hz, 1H), 7.56-7.47 (m, 7H), 7.13 (dd, *J* = 2.0, 8.8 Hz, 1H), 5.23 (s, 2H). HRMS (*m/z*) calc. for C₂₄H₁₄Cl₃N₃O₃ [M – H][–], 496.0022; observed 496.0031.

3-(2,4-dichlorophenyl)-2-(7-(2-methylbenzyloxy)-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-oxopropanenitrile (35). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.40 (br s, 1H), 8.00 (d, *J* = 8.8 Hz, 1H), 7.76 (d, *J* = 1.6 Hz, 1H), 7.57-7.51 (m, 3H), 7.44 (d, *J* = 7.2 Hz, 1H), 7.30-7.21 (m, 3H), 7.15 (dd, *J* = 2.0, 8.8 Hz, 1H), 5.23 (s, 2H), 2.34 (s, 3H). HRMS (*m/z*) calc. for C₂₅H₁₇Cl₂N₃O₃ [M – H][–], 476.0569; observed, 476.0574.

3-(2,4-dichlorophenyl)-2-(7-(3-methylbenzyloxy)-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-oxopropanenitrile (36). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.34 (br s, 1H), 7.98 (d, *J* = 8.8 Hz, 1H), 7.76 (d, *J* = 1.6 Hz, 1H), 7.56-7.48 (m, 3H), 7.31-7.25 (m, 3H), 7.18 (d, *J* = 7.2 Hz, 1H), 7.12 (dd, *J* = 2.4, 8.8 Hz, 1H), 5.18 (s, 2H), 2.32 (s, 3H). HRMS (*m/z*) calc. for C₂₅H₁₇Cl₂N₃O₃ [M – H][–], 476.0569; observed, 476.0572.

3-(2,4-dichlorophenyl)-2-(7-(4-methylbenzyloxy)-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-oxopropanenitrile (37). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.36 (br s, 1H), 7.98 (d, *J* = 8.8 Hz, 1H), 7.76 (d, *J* = 2.0 Hz, 1H), 7.57-7.47 (m, 3H), 7.38 (d, *J* = 8.0 Hz, 2H), 7.24 (d, *J* = 8.0 Hz, 2H), 7.12 (dd, *J* = 2.4, 8.8 Hz, 1H), 5.19 (s, 2H), 2.32 (s, 3H). HRMS (*m/z*) calc. for C₂₅H₁₇Cl₂N₃O₃ [M – H][–], 476.0569; observed, 476.0571.

3-(2,4-dichlorophenyl)-2-(7-(2-methoxybenzyloxy)-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-oxopropanenitrile (38). ¹H NMR (300 MHz, DMSO-*d*₆) δ 13.37 (br s, 1H), 7.96 (s, 1H), 7.77 (s, 1H), 7.55-7.38 (m, 5H), 7.13-7.00 (m, 3H), 5.19 (s, 2H), 3.84 (s, 3H). HRMS (*m/z*) calc. for C₂₅H₁₆Cl₂N₃O₄ [M – H][–], 492.0518; observed, 492.0524.

3-(2,4-dichlorophenyl)-2-(7-(3-methoxybenzyloxy)-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-oxopropanenitrile (39). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.54 (br s, 1H), 7.98 (d, *J* = 8.8 Hz, 1H), 7.75 (s, 1H), 7.53-7.04 (m, 7H), 6.93 (m, 1H), 5.20 (s, 2H), 3.76 (s, 3H). HRMS (*m/z*) calc. for C₂₅H₁₆Cl₂N₃O₄ [M – H][–], 492.0518; observed, 492.0520.

3-(2,4-dichlorophenyl)-2-(7-(4-methoxybenzyloxy)-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-oxopropanenitrile (40). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.36 (br s, 1H), 7.97 (d, *J* = 8.8 Hz, 1H), 7.75 (s, 1H), 7.56-7.49 (m, 2H), 7.43 (d, *J* = 8.4 Hz, 3H), 7.08 (d, *J* = 8.8 Hz, 1H), 6.98 (d, *J* = 8.8 Hz, 1H), 5.15 (s, 2H), 3.76 (s, 3H). HRMS (*m/z*) calc. for C₂₅H₁₆Cl₂N₃O₄ [M – H][–], 492.0518; observed, 492.0523.

2-(((2-(1-cyano-2-(2,4-dichlorophenyl)-2-oxoethylidene)-4-oxo-1,2,3,4-tetrahydroquinazolin-7-yl)oxy)methyl)benzotrile (41). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.39 (br s, 1H), 8.02 (d, *J* = 8.8 Hz, 1H), 7.96 (d, *J* = 7.6 Hz, 1H), 7.78-7.75 (m, 3H), 7.63-7.50 (m, 4H), 7.17 (dd, *J* = 2.0, 8.8 Hz, 1H), 5.40 (s, 2H). HRMS (*m/z*) calc. for C₂₅H₁₄Cl₂N₄O₃ [M – H][–], 487.0365; observed, 487.0369.

3-(((2-(1-cyano-2-(2,4-dichlorophenyl)-2-oxoethylidene)-4-oxo-1,2,3,4-tetrahydroquinazolin-7-yl)oxy)methyl)benzotrile (42). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.37 (br s, 1H), 8.00-7.97 (m, 2H), 7.87-7.83 (m, 2H), 7.77 (d, *J* = 1.6 Hz, 1H), 7.67 (t, *J* = 7.6, 15.2 Hz, 1H), 7.57-7.48 (m, 3H), 7.16 (dd, *J* = 2.0, 8.8 Hz, 1H), 5.31 (s, 2H). HRMS (*m/z*) calc. for C₂₅H₁₄Cl₂N₄O₃ [M – H][–], 487.0365; observed, 487.0370.

4-(((2-(1-cyano-2-(2,4-dichlorophenyl)-2-oxoethylidene)-4-oxo-1,2,3,4-tetrahydroquinazolin-7-yl)oxy)methyl)benzotrile (43). ¹H NMR (300 MHz, DMSO-*d*₆) δ 13.36 (br s, 1H), 8.00-7.90 (m, 3H), 7.76-7.66 (m, 3H), 7.54-7.47 (m, 3H), 7.15 (d, *J* = 8.4 Hz, 1H), 5.35 (s, 2H). HRMS (*m/z*) calc. for C₂₅H₁₄Cl₂N₄O₃ [M – H][–], 487.0365; observed, 487.0370.

3-(2,4-dichlorophenyl)-3-oxo-2-(4-oxo-7-(pyridin-2-ylmethoxy)-3,4-dihydroquinazolin-2(1H)-ylidene)propanenitrile (44). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.41 (br s, 1H), 8.63 (dd, *J* = 0.8, 4.8 Hz, 1H), 8.00 (d, *J* = 8.8 Hz, 1H), 7.90 (m, 1H), 7.76 (d, *J* = 2.0 Hz, 1H), 7.56-7.38 (m, 5H), 7.16 (dd, *J* = 2.4, 8.8 Hz, 1H), 5.32 (s, 2H). HRMS (*m/z*) calc. for C₂₃H₁₄Cl₂N₄O₃ [M – H][–], 463.0365; observed, 463.0371.

3-(2,4-dichlorophenyl)-3-oxo-2-(4-oxo-7-(pyridin-3-ylmethoxy)-3,4-dihydroquinazolin-2(1H)-ylidene)propanenitrile (45). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.57 (br s, 1H), 8.76 (s, 1H), 8.63 (d, *J* = 4.4 Hz, 1H), 8.01 (m, 2H), 7.75 (s, 1H), 7.55-7.45 (m, 4H), 7.12 (d, *J* = 8.4 Hz, 1H), 5.31 (s, 2H). HRMS (*m/z*) calc. for C₂₃H₁₄Cl₂N₄O₃ [M – H][–], 463.0365; observed, 463.0372.

3-(2,4-dichlorophenyl)-3-oxo-2-(4-oxo-7-(pyridin-4-ylmethoxy)-3,4-dihydroquinazolin-2(1H)-ylidene)propanenitrile (46). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.45 (br s, 1H), 8.66 (d, *J* = 4.4 Hz, 2H), 7.98 (d, *J* = 8.8 Hz, 1H), 7.71 (s, 1H), 7.56-7.46 (m, 4H), 7.24 (s, 1H), 7.08 (d, *J* = 8.4 Hz, 1H), 5.37 (s, 2H). HRMS (*m/z*) calc. for C₂₃H₁₄Cl₂N₄O₃ [M – H][–], 463.0365; observed, 463.0372.

2-(7-(Benzo[*d*][1,3]dioxol-5-ylmethoxy)-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-(2,4-dichlorophenyl)-3-oxopropanenitrile (47). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.33 (br s, 1H), 7.97 (s, 1H), 7.76 (s, 1H), 7.54-7.47 (m, 3H), 7.06-6.97 (m, 4H), 6.03 (s, 2H), 5.11 (s, 2H). HRMS (*m/z*) calc. for C₂₅H₁₅Cl₂N₃O₅ [M – H][–], 506.0311; observed, 506.0318.

3-(2,4-dichlorophenyl)-2-(7-((4-(methylsulfonyl)benzyl)oxy)-4-oxo-3,4-dihydroquinazolin-2(1H)-ylidene)-3-oxopropanenitrile (48). ¹H NMR (400 MHz, DMSO-*d*₆) δ 13.35 (br s, 1H), 8.01-7.97 (m, 3H), 7.76-7.74 (m, 3H), 7.57-7.50 (m, 3H), 7.16 (dd, *J* = 2.4, 8.8 Hz, 1H), 5.39 (s, 2H), 3.23 (s, 3H). HRMS (*m/z*) calc. for C₂₅H₁₇Cl₂N₃O₅S [M – H][–], 540.0188; observed, 540.0193.

MATERIALS AND METHODS — BIOCHEMICAL AND CELLULAR ASSAYS

Generation of stable DYNC1H1- and DYNC2H1-expressing cells

Flp-In T-Rex 293 cells (Invitrogen) were seeded at 2.5 million cells/15-cm plate in DMEM containing 10% (v/v) fetal bovine serum (FBS), 100 U/mL penicillin, and 0.1 mg/mL streptomycin and cultured for 22 h. A 500- μ L solution of 0.25 M CaCl_2 , 9.0 μ g pOG44 (Invitrogen), and 1.0 μ g of either SBP-SNAP-DYNC1H1 or SBP-SNAP-DYNC2H1 plasmids (which encode the full-length human cytoplasmic dynein 1 and 2 heavy chains with N-terminal streptavidin-binding peptide (SBP) and SNAP tags),³ was then slowly added to 500 μ L HEPES buffered saline (280 mM NaCl, 1.5 mM Na_2HPO_4 , 50 mM HEPES, pH 7.0) and allowed to sit for one minute. The resulting turbid solution was added dropwise to one plate of Flp-In T-Rex 293 cells, and the cells were cultured for 48 h with a media change at 24 h. The cells were then split into selection medium (DMEM containing 10% (v/v) FBS, 100 U/mL penicillin, 0.1 mg/mL streptomycin, 10 μ g/mL blasticidin, and 100 μ g/mL hygromycin B) and cultured to give colonies of stably-transfected cells.

Expression and purification of SBP-SNAP-DYNC1H1 and SBP-SNAP-DYNC2H1

Two hundred 15-cm plates of either SBP-SNAP-DYNC1H1- or SBP-SNAP-DYNC2H1-expressing Flp-In T-Rex 293 cells were cultured to 70% confluency in DMEM containing 10% (v/v) FBS, 100 U/mL penicillin, 0.1 mg/mL streptomycin, 10 μ g/mL blasticidin, and 100 μ g/mL hygromycin B. Doxycycline (2 μ g/mL) was added, and the cells were cultured for an additional 48 h. The cells were then harvested via trypsinization and centrifugation at 200 g, resuspended in 200 mL of ice-cold lysis buffer (25 mM HEPES, 50 mM PIPES, 2 mM MgSO_4 ,

0.2 mM EGTA, 0.1% (v/v) Triton X-100, 1 mM DTT, 2 mM PMSF, Complete MiniProtease Inhibitor (Roche), pH 7.5), and sonicated on ice until the cells were completely homogenized. Lysates were cleared by centrifugation at 30,000 g for 30 min at 4 °C, and incubated with 5 mL of Streptavidin High Performance Beads (GE Healthcare) for 4 h at 4 °C. The matrix was washed with 100 mL of lysis buffer and added to a 1 cm x 15 cm glass Econo-Column (Bio-Rad), and the SBP-SNAP-DYNC1H1 or SBP-SNAP-DYNC2H1 protein was eluted in 25 x 500- μ L aliquots with lysis buffer containing 2 mM biotin. The aliquots were analyzed on a 3-8% Tris-Glycine SDS-PAGE gel (Bio-Rad), and protein-containing fractions were pooled and dialyzed in 1 L of assay buffer (50 mM Tris-HCl, 150 mM KOAc, 2 mM Mg(OAc)₂, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, pH 8) overnight. Protein concentrations were quantified using Bradford reagent, and the purified heavy chains were snap-frozen in assay buffer containing 1% (v/v) glycerol using liquid nitrogen and stored at -80 °C.

Expression and purification of 6xHis-DYNC1H1 and GFP-DYNC2H1 motor domains

The motor domains of DYNC1H1 (amino acids 1320-4647) and DYNC2H1 (amino acids 1091-4307) were expressed in insect cells and purified as described below. In the case of the DYNC1H1 motor, an N-terminal 6x-His tag was used for affinity-based purification. Construct preparation was performed as follows: A human *DYNC1H1* cDNA clone (pF1KA0325) was obtained from Kazusa DNA Research Institute, and the coding region that encompasses the motor domain (residues Q1320 - V4647) was amplified and fused with a hexahistidine (His₆)-tag by PCR using Phusion High-Fidelity DNA Polymerase (NEB). The assembled construct was cloned into a pFastBac (Invitrogen) vector using an InFusion HD cloning Kit (Clontech Laboratories).

Purification of the DYNC1H1 motor domain proceeded as follows: An Sf9 cell pellet was resuspended in a buffer containing, 30mM HEPES pH 7.6, 200 mM NaCl, 10 mM imidazole, 1 mM TCEP, 2 mM PMSF, HALT (Thermo Fisher) and complete protease inhibitor cocktail (Roche) and lysed by the addition of Triton X-100 to a final concentration of 0.2% (v/v). The lysate was clarified by centrifugation at 140,000 g and then incubated with Ni-NTA beads for 2 h at 4 °C. The beads were washed with 75 bed volumes of lysis buffer, and bound proteins were eluted with buffer containing 30 mM HEPES pH 7.5, 100 mM NaCl, 500 mM imidazole, and 1 mM TCEP. Eluate fractions containing the DYNC1H1 motor domain were diluted into gel-filtration buffer (50 mM Tris HCl pH 7.8, 150 mM KOAc, 2 mM Mg(OAc)₂, 1 mM EGTA, 1 mM EDTA, 0.1 mM ATP, and 1 mM DTT) and loaded onto a Mono Q anion exchange column (GE Healthcare). The column was eluted using a salt gradient from 150 to 750 mM KOAc over 20 column volumes. Peak fractions were concentrated using a centrifugal concentrator (Amicon) and subjected to size-exclusion chromatography on a Superose 6 column using gel filtration buffer. Gel filtration revealed a monodisperse peak at an elution volume of 12.2 mL, consistent with the expected molecular weight. Peak fractions were pooled, supplemented with glycerol to a final concentration of 20% (v/v), and snap frozen. The protein yield was ~ 1 mg of DYNC1H1 motor domain per 1 L of Sf9 culture.

The DYNC2H1 motor domain was prepared as described previously.⁴ Briefly, the protein was expressed with N-terminal protein A tag and GFP tags separated by a tobacco etch virus (TEV) protease site and purified using IgG-Sepharose. The protein A tag was then proteolytically removed, and gel filtration of the product revealed a monodisperse peak at an elution volume of 12.6 mL, consistent with the expected molecular weight.

DYNC1H1 and DYNC2H1 ATPase assays

The ATPase activities of purified SBP-SNAP-DYNC1H1 and SBP-SNAP-DYNC2H1 proteins were measured through the kinetic hydrolysis of γ - ^{32}P ATP. Individual 25- μL reactions were prepared in 96-well plates, each containing assay buffer (50 mM Tris-HCl, 150 mM KOAc, 2 mM $\text{Mg}(\text{OAc})_2$, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, pH 8) supplemented with 0.056 $\mu\text{g}/\text{mL}$ of SBP-SNAP-DYNC1H1 or SBP-SNAP-DYNC2H1, 0.1% (w/v) BSA, 0.1% (v/v) Triton X-100, and either a ciliobrevin analog or an equivalent amount of DMSO vehicle (4%, v/v). The reactions were initiated by the addition of 1.6 μCi γ - ^{32}P ATP (Perkin Elmer; final concentration of 18-26 nM) and incubated at 37 °C for 12 min on a thermocycler. A 2.5- μL aliquot of each reaction was subsequently mixed with 300 μL of charcoal suspension (0.6 M acetic acid, 2.5 mM KH_2PO_4 , and 4% (w/v) activated charcoal) and centrifuged to obtain a supernatant containing the hydrolyzed ^{32}P orthophosphate. A 100- μL fraction of this supernatant was added to 1 mL of Ultima Gold scintillation cocktail (Perkin Elmer) and ^{32}P orthophosphate emissions were measured on a Beckman Coulter LS6500 liquid scintillation counter.

The ATPase activities of purified 6xHis-DYNC1H1 and GFP-DYNC2H1 motor domains were assayed in buffer containing 25 mM PIPES pH 7.0, 30 mM KCl, 1 mM EGTA, 5 mM MgCl_2 , 0.01% (v/v) Triton X-100, 1 mM DTT, and 0.1 mg/mL BSA. For all conditions, the enzymes were incubated with varying concentrations of inhibitor in 2% DMSO for 10 minutes in a volume of 10 μL . Each ATPase reaction was initiated by addition of 2 μL of a 6x ATP stock containing trace γ - ^{32}P ATP (6000 Ci/mmol, 10 mCi/mL, Perkin Elmer) and allowed to proceed at room temperature for a time predetermined to lie within the linear range of the assay. For the “low ATP” conditions, final concentrations of 1 nM dynein motor and 25 nM ATP were used, and the reaction was allowed to proceed for 10 minutes. For the “high ATP” conditions, final

concentrations of 30 nM dynein and 100 μ M ATP were used, and the reaction was allowed to proceed for 30 minutes. Reactions were quenched by the addition of 100 mM EDTA, and 2 μ L of each reaction was spotted onto PEI-cellulose thin layer chromatography plates (Millipore). The plates were developed in a glass chamber with a freshly prepared solution of 150 mM formic acid and 150 mM LiCl, dried, exposed to a storage phosphor tray, and scanned on a Typhoon imaging system (GE Healthcare Life Sciences). The fraction of γ -phosphate hydrolyzed in each condition was quantified using ImageJ and normalized to a DMSO control.

Hh signaling assays

Shh-LIGHT2 cells,⁵ an NIH-3T3 cell line stably integrated with Gli-dependent firefly luciferase and thymidine kinase promoter-driven *Renilla* luciferase reporters, were cultured in DMEM containing 10% calf serum (CS), 100 U/mL penicillin, 0.1 mg/mL streptomycin, 1 mM sodium pyruvate, 400 μ g/mL G418, and 150 μ g/mL zeocin. The cells were seeded at 35,000 cells/well in a 96-well plate and treated with individual ciliobrevin analogs or an equivalent amount of DMSO vehicle (1%, v/v) in DMEM containing 0.5% CS and 10% ShhN-conditioned medium.⁶ After 30 h, the cells were lysed, and their firefly and *Renilla* luciferase activities were measured using a Dual Luciferase Reporter kit (Promega) and a Veritas microplate luminometer. Dose-response data were curve-fitted with a variable slope, sigmoidal dose-response algorithm using Prism software (GraphPad) to obtain IC₅₀ values.

Ciliogenesis assays

Shh-EGFP cells,⁷ an NIH-3T3 cell line stably integrated with a Gli-dependent green fluorescent protein reporter, were cultured in DMEM containing 10% CS, 100 U/mL penicillin,

0.1 mg/mL streptomycin, 1 mM sodium pyruvate, and 150 μ g/mL zeocin. The cells were seeded onto poly-D-lysine-coated, 12-mm glass coverslips in 24-well plates at a density of 35,000 cells/well and cultured for 40 h. The media was then replaced with DMEM containing 0.5% CS, 100 U/mL penicillin, 0.1 mg/mL streptomycin, 1 mM sodium pyruvate, and either an individual ciliobrevin analog (30 μ M) or an equivalent amount of DMSO vehicle (0.3%, v/v). Following a 24-h incubation, the cells were fixed in PBS containing 4% (w/v) paraformaldehyde for 10 min at room temperature, washed 3 x 5 min with PBS, permeabilized with PBS containing 0.3% (v/v) Triton X-100 for 5 min, washed 2 x 5 min with PBS, and then blocked overnight at 4 °C in PBS containing 1% (w/v) BSA and 0.1% (v/v) Triton X-100. The coverslips were next treated overnight at 4 °C with blocking buffer containing mouse monoclonal anti-ARL13B antibody (1:1000; UC-Davis/NIH NeuroMab Facility, 75-287), washed 3 x 5 min with PBS containing 0.1% (v/v) Triton X-100, treated for 1 h at room temperature with blocking buffer containing AlexaFluor 488-conjugated goat polyclonal anti-mouse IgG antibody (1:400 dilution; Invitrogen, A-11029), washed 3 x 5 min with PBS containing 0.1% (v/v) Triton X-100, and mounted onto glass slides with Prolong Gold Antifade reagent containing DAPI (Invitrogen). The immunostained cells were then imaged on a Leica DMI6000B compound microscope equipped with an HC Pan Apochromat CS 20x/0.70 NA oil-immersion objective, a Photometric CoolSNAP HQ CCD camera, and Metamorph software (Molecular Devices).

To quantify primary cilia lengths, the minimum threshold intensity for cilia staining was first established by manual inspection, and ImageJ software was used to quantify the total pixel area of ARL13B-positive pixels equal to or greater than the minimum threshold intensity. The average cilia length was then determined by dividing the number of ARL13B-positive pixels by the number of DAPI-positive nuclei in each field of view, and at least 6 fields of view were

analyzed per experimental condition. Approximately 800 cells/condition were analyzed in this manner, although fewer cells were imaged in some cases due to decreased cell viability. Analogs **8**, **12**, **19**, **23**, and **40** could not be analyzed in this assay due to the formation of precipitates that interfered with fluorescence imaging.

IFT88 trafficking assays

Shh-EGFP cells were seeded onto poly-D-lysine-coated, 12-mm glass coverslips in 24-well plates at a density of 125,000 cells/well and cultured for 24 h in the DMEM/10% CS medium described above. The cells were next cultured in DMEM containing 0.5% CS, 100 U/mL penicillin, and 0.1 mg/mL streptomycin for 16 h to promote primary cilia formation, and then transferred into the low-serum medium containing either individual ciliobrevin analogs (50 μ M) or an equivalent amount of DMSO vehicle (0.25%, v/v) for 1 h. After compound treatment, the Shh-EGFP cells were fixed in PBS containing 4% (w/v) paraformaldehyde for 8 min at room temperature, washed 1 x with PBS before addition of ice-cold (-20 °C) methanol for 5 min at -20 °C. For wash-out experiments, cells were incubated with low-serum medium after compound treatment for 10 min, and transferred into fresh low-serum medium for an additional 4 h at 37 °C before fixing the cells as described above. Subsequently, cells were washed 1 x with PBS and 2 x with PBS containing 0.1% (v/v) Triton X-100, and blocked for 1 h at room temperature in PBS containing 1% (w/v) BSA and 0.1% (v/v) Triton X-100. The coverslips were subsequently treated with blocking buffer containing mouse monoclonal anti-ARL13B IgG2a antibody (1:3000; UC-Davis/NIH NeuroMab Facility, 75-287) overnight at 4 °C, washed 1 x 5 min in PBS containing 0.1% (v/v) Triton X-100, and then incubated with blocking buffer containing rabbit polyclonal anti-IFT88 antibody (1:70 dilution; ProteinTech

Group, 13967-1-AP) and mouse monoclonal anti- γ -Tubulin IgG1 antibody (1:500 dilution; Sigma, T6557, clone GTU-88, ascites fluid) for 90 min at room temperature. The immunostained cells were washed 4 x 5 min with PBS containing 0.1% (v/v) Triton X-100 and incubated in blocking buffer containing Alexa Fluor 488-conjugated goat polyclonal anti-rabbit IgG antibody (1:300 dilution; Invitrogen, A-11034), Alexa Fluor 594-conjugated goat polyclonal anti-mouse IgG1 antibody (1:500 dilution; Jackson ImmunoResearch, 115-585-205), Alexa Fluor 647-conjugated goat polyclonal anti-mouse IgG2a antibody (1:500 dilution; Jackson ImmunoResearch, 115-605-206) for 1 h at room temperature. Following the secondary antibody incubation, cells were washed 5 x 5 min with PBS containing 0.1% (v/v) Triton X-100. The coverslips were mounted onto glass slides using Prolong Gold Antifade reagent containing DAPI (Invitrogen) to stain nuclei and imaged at 500-nm z intervals on a Zeiss microscope (Axio Imager.M1) using epifluorescent illumination (Lambda XL light source; Sutter Instrument) through a 63x/1.4 NA Plan Apochromat objective. Images were captured with a camera (CoolSNAP HQ²; Photometrics) using SlideBook software (Intelligent Imaging Innovations).

Quantitative image analyses were conducted using MatLab R2014A (Mathworks). ARL13B staining was used to mask and track the cilia and the γ -tubulin staining was used to orient the cilia from base to tip. The IFT88 signal along each axoneme was analyzed by dividing the total length of the cilium (as measured from the ARL13B staining) in 21 bins, each consisting of a 2-pixel-radius circle. Overlap correction was used to make sure that the summed fluorescence intensities over the 21 bins did not exceed the total ciliary fluorescence signal. The IFT88 signal within each bin was then normalized to the total ciliary signal to determine the fraction of ciliary IFT88 protein localized to each position along the axoneme. IFT88 signals

from 70-120 cilia were analyzed from 5 fields of view to obtain traces for each compound, and the experiments were performed in duplicate.

To assess the effects of ciliobrevins on IFT88 movement in real time, murine inner medullary collecting duct (IMCD3) cells stably expressing mNeonGreen-IFT88 were imaged as previously described.⁸ The cells were seeded on 25-mm coverslips and serum-starved for 24 h to induce ciliation. Imaging was conducted in phenol red-free media and on a DeltaVision system (Applied Precision) equipped with a PlanApo 603/1.49 NA internal reflection microscopy (TIRF) oil-immersion objective (Olympus). Images were captured with an sCMOS camera (Applied Precision) at 2 Hz, and line scan kymographs were generated by ImageJ. Velocities and frequencies of mNeonGreen-IFT88 foci movements were then quantified from the kymographs.

Mitotic spindle morphology assays

Shh-EGFP cells were seeded onto poly-D-lysine-coated, 12-mm glass coverslips in 24-well plates at a density of 60,000 cells/well and cultured for overnight in the DMEM/10% CS medium described above. The cells were then cultured in the same growth medium containing 15 μ M MG132 for 90 min, following by a 30-min incubation with DMEM containing 0.5% CS, 15 μ M MG132, and either individual ciliobrevin analogs or an equivalent amount of DMSO vehicle (0.3%, v/v). The Shh-EGFP cells were treated with methanol chilled to -20 °C for 10 min, washed 3 x 5 min with PBS containing 0.1% (v/v) Triton X-100, and blocked for 1 h at room temperature with PBS containing 1% (w/v) BSA and 0.1% (v/v) Triton X-100. The cells were subsequently incubated with blocking buffer containing mouse monoclonal anti- α -tubulin antibody (1:2000 dilution, Sigma-Aldrich, T6199) and rabbit polyclonal anti- γ -tubulin antibody (1:1500 dilution, Sigma-Aldrich, T3559) overnight at 4 °C. The immunostained cells were

washed 3 x 5 min with PBS containing 0.1% (v/v) Triton X-100 and incubated with blocking buffer containing Alexa Fluor 488-conjugated goat polyclonal anti-rabbit IgG antibody (1:400 dilution; Invitrogen, A-11034) and Alexa Fluor 594-conjugated goat polyclonal anti-mouse IgG antibody (1:400 dilution; Invitrogen, A-11032) for 1 h at room temperature. The coverslips were washed 3 x 5 min in PBS containing 0.1% (v/v) Triton X-100, mounted onto slides using Prolong Gold Antifade reagent containing DAPI (Invitrogen), and imaged using a Zeiss LSM700 confocal laser-scanning microscope equipped with a Plan Apochromat 63x/1.4 NA oil-immersion objective. At least 200 mitotic spindles were analyzed for each experimental condition.

Golgi dispersion and GLI2 trafficking assays

Shh-EGFP cells were seeded onto poly-D-lysine-coated, 12-mm glass coverslips in 24-well plates at a density of 125,000 cells/well and cultured for 24 h in the DMEM/10% CS medium described above. The cells were next cultured in DMEM containing 0.5% CS, 100 U/mL penicillin, and 0.1 mg/mL streptomycin for 16 h to promote primary cilia formation, and then transferred into the low-serum medium containing either individual ciliobrevin analogs (5, 10, 20, or 30 μ M) or an equivalent amount of DMSO vehicle (0.25%, v/v) for 4 h. After compound treatment, the Shh-EGFP cells were fixed in PBS containing 4% (w/v) paraformaldehyde for 10 min at room temperature, washed 2 x 5 min with PBS, permeabilized for 5 min with PBS containing 0.3% (v/v) Triton X-100 and washed 3 x 5 min with PBS. Subsequently, coverslips were blocked for 1 h at room temperature in PBS containing 1% (w/v) BSA and 0.1% (v/v) Triton X-100. The coverslips were subsequently treated with blocking buffer containing mouse monoclonal anti-ARL13B IgG2a antibody (1:3000 dilution; UC-

Davis/NIH NeuroMab Facility, 75-287) and goat polyclonal anti-GLI2 antibody (1:100 dilution; R&D systems, AF3635) overnight at 4 °C, washed 1 x 5 min in PBS containing 0.1% (v/v) Triton X-100, and then incubated with blocking buffer containing rabbit monoclonal anti-GM130 antibody (1:500 dilution; Abcam, ab52647) for 90 min at room temperature. The immunostained cells were washed 4 x 5 min with PBS containing 0.1% (v/v) Triton X-100 and incubated in blocking buffer containing Alexa Fluor 488-conjugated donkey polyclonal anti-goat IgG antibody (1:300 dilution; Invitrogen, A-11055), Alexa Fluor 594-conjugated donkey polyclonal anti-mouse IgG antibody (1:300 dilution; Invitrogen, A21203), Alexa Fluor 647-conjugated donkey polyclonal anti-rabbit IgG antibody (1:300 dilution; Invitrogen, A-31573) for 1 h at room temperature. Following the secondary antibody incubation, cells were washed 5 x 5 min with PBS containing 0.1% (v/v) Triton X-100. The coverslips were mounted onto glass slides using Prolong Gold Antifade reagent containing DAPI (Invitrogen) to stain nuclei and imaged at 500-nm z intervals on a Zeiss microscope (Axio Imager M1) using epifluorescent illumination (Lambda XL light source; Sutter Instrument) and a 63x/1.4 NA Plan Apochromat objective. Images were captured with a CoolSNAP HQ² camera (Photometrics) using SlideBook software (Intelligent Imaging Innovations).

Quantitative image analyses were conducted using MatLab R2014A (Mathworks). Golgi dispersal was analyzed by scoring specific morphologies as described in Figure S2. ARL13B staining was used to mask and track individual cilia, and GLI2 staining was used to designate the distal tip of each cilium. Each axenome was divided in 21 bins as described above, and the absolute fluorescent GLI2 signal at the ciliary tip (bin 19; maximum GLI2 signal) was averaged over 100-300 cilia analyzed from 4-6 fields of view. The GLI2 signal for each compound was



then normalized to that observed in cells treated with the Hh pathway activator SAG. Three independent experiments were analyzed.

REFERENCES



1. Firestone, A. J., Weinger, J. S., Maldonado, M., Barlan, K., Langston, L. D., O'Donnell, M., Gelfand, V. I., Kapoor, T. M., and Chen, J. K. (2012) Small-molecule inhibitors of the AAA+ ATPase motor cytoplasmic dynein, *Nature* 484, 125-129.
2. Sikirzhyski, V., Magidson, V., Steinman, J. B., He, J., Le Berre, M., Tikhonenko, I., Ault, J. G., McEwen, B. F., Chen, J. K., Sui, H., Piel, M., Kapoor, T. M., and Khodjakov, A. (2014) Direct kinetochore-spindle pole connections are not required for chromosome segregation, *J. Cell Biol.* 206, 231-243.
3. Ichikawa, M., Watanabe, Y., Murayama, T., and Toyoshima, Y. Y. (2011) Recombinant human cytoplasmic dynein heavy chain 1 and 2: observation of dynein-2 motor activity in vitro, *FEBS Lett.* 585, 2419-2423.
4. Schmidt, H., Zalyte, R., Urnavicius, L., and Carter, A. P. (2015) Structure of human cytoplasmic dynein-2 primed for its power stroke, *Nature* 518, 435-438.
5. Taipale, J., Chen, J. K., Cooper, M. K., Wang, B., Mann, R. K., Milenkovic, L., Scott, M. P., and Beachy, P. A. (2000) Effects of oncogenic mutations in Smoothed and Patched can be reversed by cyclopamine, *Nature* 406, 1005-1009.
6. Chen, J. K., Taipale, J., Young, K. E., Maiti, T., and Beachy, P. A. (2002) Small molecule modulation of Smoothed activity, *Proc. Natl. Acad. Sci. U. S. A.* 99, 14071-14076.
7. Hyman, J. M., Firestone, A. J., Heine, V. M., Zhao, Y., Ocasio, C. A., Han, K., Sun, M., Rack, P. G., Sinha, S., Wu, J. J., Solow-Cordero, D. E., Jiang, J., Rowitch, D. H., and Chen, J. K. (2009) Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade, *Proc. Natl. Acad. Sci. U. S. A.* 106, 14132-14137.


8. Liew, G. M., Ye, F., Nager, A. R., Murphy, J. P., Lee, J. S., Aguiar, M., Breslow, D. K., Gygi, S. P., and Nachury, M. V. (2014) The intraflagellar transport protein IFT27 promotes BBSome exit from cilia through the GTPase ARL6/BBS3, *Dev. Cell* 31, 265-278.

Compound 01 (Ciliobrevin A)




Compound 02 (Ciliobrevin D)





NOESY 400M
20111009-3

Compound 03




Current Data Parameter
NAME 20111009-
EXPNO
PROCNO


F2 - Acquisition Param
Date_ 2011100
Time 19.1
INSTRUM spec
PROBHD 5 mm PABBO BE
PULPROG zg3
TD 6553
SOLVENT DMS
NS
DS
SWH 8012.82
FIDRES 0.12226
AQ 4.089496
RG 109.2
DW 62.40
DE 6.5
TE 297.
D1 1.0000000

==== CHANNEL f1 ==
NUC1 1

7.659
7.749
7.745
7.731
7.672
7.651
7.557
7.553
7.536
7.532
7.507
7.486

Water 3.391
DMSO 2.492
2.405





2011020-3
EXPNO 1
PROCNO 1
Date_ 20111020
Time 19.02
INSTRUM AV500
PROBHD 5 mm PABBO BB-
PULPROG zg30
TD 32768
SOLVENT DMSO
NS 16
DS 0
SWH 10330.578 Hz
FIDRES 0.315264 Hz
AQ 1.5860696 sec
RG 256
DW 48.400 usec
DE 6.00 usec
TE 300.3 K
D1 1.0000000 sec
TD0 1

CHANNEL f1
NUC1 1H
P1 10.00 usec
PL1 -0.79 dB
PL1W 25.30924988 W
SFO1 500.1330885 MHz
SI 32768
SF 500.1300092 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00

13.4562



2011020-3
DMSO

7.9499
7.9338
7.7469
7.6497
7.5503
7.5356
7.5085
7.4922
7.3080
7.2922

3.3315

2.4894
2.4375

Compound 04



HPI-4

20130426-HPI-93

Compound 05

6-24
6-27

13.570
13.544
13.365
13.337


10 40% 40%
2013-6-9

7.879
7.796
7.775
7.775
7.761
7.727
7.707
7.585
7.546
7.522
7.502

3.364

2.736
2.718
2.501

1.237
1.220
1.202




Current Data Parameters
 NAME 20130426-HPI-93
 EXPNO 1
 PROCNO 1


F2 - Acquisition Parameters
 Date_ 20130426
 Time_ 16.22
 INSTRUM spect
 PROBHD 5 mm PABBO BB-
 PULPROG zg30
 TD 65536
 SOLVENT DMSO
 NS 4
 DS 2
 SWH 8012.820 Hz
 FIDRES 0.122266 Hz
 AQ 4.0894966 sec
 RG 127.33
 DW 62.400 usec
 DE 6.50 usec
 TE 0 K
 D1 1.00000000 sec

==== CHANNEL f1 =====
 NUC1 1H
 P1 15.00 usec
 PLW1 12.00000000 W
 SF01 400.1326008 MHz

F2 - Processing parameters
 SI 65536
 SF 400.1300037 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00



Compound 06



NOESY 400M

Current 13433
 NAME 13421 HPI-95
 EXPNO 1
 PROCNO 13402
 Parameters
 HPI-95
 1
 1


F2 - Acquisition Parameters
 Date_ 20130427
 Time 16.05
 INSTRUM spect
 PROBHD 5 mm PABBO BB-
 PULPROG zg30
 TD 65536
 SOLVENT DMSO
 NS 8
 DS 2
 SWH 8012.820 Hz
 FIDRES 0.122266 Hz
 AQ 4.0894966 sec
 RG 195.79
 DW 62.400 use
 DE 6.50 use
 TE 0 K
 D1 1.00000000 sec

----- CHANNEL f1 -----
 NUC1 1H
 P1 15.00 use
 PLW1 12.00000000 W
 SFO1 400.1326008 MHz


7.975
 7.955
 7.757
 7.752
 7.712
 7.563
 7.558
 7.542
 7.535
 7.516
 7.496
 7.356
 7.335

3.347
 2.776
 2.757
 2.738
 2.720
 2.497
 2.493
 2.489

1.247
 1.228
 1.209



Compound 07



NOESY 400M

7.891
7.887
7.816
7.795
7.784
7.779
7.758
7.754
7.563
7.558
7.542
7.537
7.515
7.495

3.370
3.072
3.054
3.037
3.020
3.002
2.496
2.482
2.488


1.248
1.231

Current Data Parameters
NAME HPI-94
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 20130426
Time_ 16.14
INSTRUM spect
PROBHD 5 mm PABBO BB-
PULPROG zg30
TD 65536
SOLVENT DMSO
NS 6
DS 2
SWH 8012.820 Hz
FIDRES 0.122266 Hz
AQ 4.0894966 sec
RG 195.79
DW 62.400 usec
DE 6.50 usec
TE 0 K
D1 1.00000000 sec

===== CHANNEL f1 =====
NUC1 1H
P1 15.00 usec
PLW1 12.00000000 W
SFO1 400.1326008 MHz

F2 - Processing parameters
SI 65536
SF 400.1300068 MHz




20130424-HPI-96

Compound 08


NAME 20130424-HPI-95
EXPNO 21
PROCNO 1
Date 20130424
Time 13:47:56
INSTRUM spect
PROBHD 5 mm PADUL 13C
PULPROG zg
TD 65536
SOLVENT DMSO
NS 8
DS 0
SWH 5995.204 Hz
FIDRES 0.091480 Hz
AQ 5.4657526 sec
RG 181
DW 83.400 usec
DE 6.50 usec
TE 292.2 K
D1 2.00000000 sec
TD0 1

7.995
7.968
7.779
7.773
7.583
7.577
7.555
7.549
7.530
7.503
7.418
7.414
7.391
7.387

3.565
3.386
3.056
3.033
3.011
2.508
2.502
2.497
1.988
1.262
1.239



===== CHANNEL f1 =====
NUC1 1H
P1 11.25 usec
PL1 0.00 dB
PL1W 8.31434441 W
SFO1 300.1318458 MHz
SI 32768
SF 300.1300000 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00



20120517-HPI-082




Compound 10


Current Data Parameters
NAME 20120517-HPI-082
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date 20120516
Time 14.21
INSTRUM spect
PROBHD 5 mm PABBO BB-
PULPROG zg30
TD 65536
SOLVENT CDCl3
NS 8
DS 2
SWH 8012.820 Hz
FIDRES 0.122266 Hz
AQ 4.0894966 sec
RG 195.79
DW 62.400 usec
DE 6.50 usec
TE 297.3 K
D1 1.0000000 sec

----- CHANNEL f1 -----
NUC1 1H
P1 15.00 usec
PLW1 12.0000000 W
SFO1 400.1326008 MHz

F2 - Processing parameters
SI 65536
SF 400.1300037 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00





HPI-07

Current Data Parameter
 NAME 20110930-
 EXPNO
 PROCNO

F2 - Acquisition Param
 Date 2011093
 Time 16.2
 INSTRUM spec
 PROBHD 5 mm PABBO BB
 PULPROG zg3
 TD 6553
 SOLVENT DMS
 NS
 DS
 SWH 8012.82
 FIDRES 0.12226
 AQ 4.089496
 RG 195.7
 DW 62.40
 DE 6.5
 TE 296.
 D1 1.0000000

==== CHANNEL f1 ==
 NUC1 1

NOESY 400M
 20110930-2



7.832
 7.808
 7.749
 7.556
 7.535
 7.510
 7.489
 7.475
 7.460


3.864

3.361

2.493



Compound 11






20130530-HPI-097

Compound 13



Compound 14



NOESY 400M

HPI-99
 7.955, 7.933, 7.754, 7.749, 7.562, 7.557, 7.541, 7.536, 7.515, 7.494, 7.378, 7.027, 7.021, 7.005, 6.999

4.181, 4.164, 4.147, 4.129

3.349

2.497, 2.492, 2.488


1.397, 1.380, 1.362, 1.224

Current Data Parameters
 NAME HPI-99
 EXPNO 1
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20130527
 Time 15.27
 INSTRUM spect
 PROBHD 5 mm PABBO BB-
 PULPROG zg30
 TD 65536
 SOLVENT DMSO
 NS 10
 DS 2
 SWH 8012.820 Hz
 FIDRES 0.122266 Hz
 AQ 4.0894966 sec
 RG 195.79
 DW 62.400 usec
 DE 6.50 usec
 TE 298.5 K
 D1 1.00000000 sec

----- CHANNEL f1 -----
 NUC1 1H
 P1 15.00 usec
 PLW1 12.00000000 W
 SFO1 400.1326008 MHz

F2 - Processing parameters
 SI 65536
 SF 400.1300068 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00



20130529-HPI-98

13.538

NAME 20130529-HPI-98
EXPNO 21
PROCNO 1
Date 20130531
Time 11.17
INSTRUM spect
PROBHD 5 mm PADUL 13C
PULPROG zg
TD 65536
SOLVENT DMSO
NS 8
DS 0
SWH 5995.204 Hz
FIDRES 0.091480 Hz
AQ 5.4657526 sec
RG 128
DW 83.400 usec
DE 6.50 usec
TE 294.1 K
D1 2.00000000 sec
TD0 1

===== CHANNEL f1 =====
NUC1 1H
P1 11.25 usec
PL1 0.00 dB
PL1W 8.31434441 W
SFO1 300.1318458 MHz
SI 32768
SF 300.1300000 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00


7.826
7.794
7.766
7.760
7.574
7.568
7.547
7.540
7.518
7.490
7.478
7.452

4.066
4.044
4.023
3.366
2.508
2.502
2.497
1.800
1.777
1.754
1.730
1.232
1.022
0.998
0.973


Water

DMSO

Compound 15



TMS



HPI-100

NAME HPI-100
EXPNO 21
PROCNO 1
Date 20130530
Time 13.51
INSTRUM spect
PROBHD 5 mm PADUL 13C
PULPROG zg
TD 65536
SOLVENT DMSO
NS 8
DS 0
SWH 5995.204 Hz
FIDRES 0.091480 Hz
AQ 5.4657526 sec
RG 161.3
DW 83.400 usec
DE 6.50 usec
TE 293.3 K
D1 2.0000000 sec
TD0 1



----- CHANNEL f1 -----
NUC1 1H
P1 11.25 usec
PL1 0.00 dB
PL1W 8.31434441 W
SFO1 300.1318458 MHz
SI 32768
SF 300.1300000 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00

7.962
7.932
7.770
7.576
7.550
7.529
7.502
7.403
7.045
7.016

4.069
4.049
4.027
3.382


2.503
1.822
1.800
1.778
1.756
1.228
1.018
0.994
0.970

Compound 16



20130607-HPI-101

Compound 17




Current Data Parameters
NAME 20130607-HPI-101
EXPNO 1
PROCNO 1

F2 - Acquisition Parameters
Date_ 20130608
Time 11.04
INSTRUM spect
PROBHD 5 mm PABBO BB-
PULPROG zg30
TD 65536
SOLVENT DMSO
NS 8
DS 2
SWH 8012.820 Hz
FIDRES 0.122266 Hz
AQ 4.0894966 sec
RG 195.79
DW 62.400 usec
DE 6.50 usec
TE 299.2 K
D1 1.00000000 sec



----- CHANNEL f1 -----
NUC1 1H
P1 15.00 usec
PLW1 12.00000000 W
SFO1 400.1326008 MHz

F2 - Processing parameters
SI 65536
SF 400.1300037 MHz
WDW EM
SSB 0
LB 0.30 Hz
GB 0
PC 1.00




20130607-HPI-102

Compound 18





Tommaso - Bruker 400MHz
Chemistry Ciliobrevin
TC-100/CBN84
1H_DMSO-d6
0.6ml (0.05%TMS)




7.762
7.743
7.743
7.556
7.532
7.509
7.488
7.364
7.356
7.341
7.334
7.144
7.137

~~~~~


Compound 19





NOESY 400M  
20111116-2

Compound 20



Current Data Parameters  
NAME 20111116-2  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20111116  
Time\_ 15.56  
INSTRUM spect  
PROBHD 5 mm PABBO BB-  
PULPROG zg30  
TD 65536  
SOLVENT CDCl3  
NS 8  
DS 2  
SWH 8012.820 Hz  
FIDRES 0.122266 Hz  
AQ 4.0894966 s  
RG 195.79  
DW 62.400 us  
DE 6.50 us  
TE 296.8 K  
D1 1.0000000 s


----- CHANNEL f1 -----  
NUC1 1H  
P1 15.00 us  
PLW1 12.0000000 W  
SFO1 400.1326008 MHz

F2 - Processing parameters  
SI 65536  
SF 400.1300068 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00

8.268  
8.265  
8.248  
7.828  
7.824  
7.807  
7.789  
7.785  
7.785  
7.497  
7.482  
7.480  
7.462  
7.460  
7.435  
7.415  
7.388  
7.378  
7.369  
7.365  
7.349  
7.345  
7.268



3.973

1.573




20111017-HPI-016

Compound 21



15.654



Current Data Parameters  
NAME 201111-24-1  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20111124  
Time 9.27  
INSTRUM spect  
PROBHD 5 mm F4013  
PULPROG zg30  
TD 65536  
SOLVENT CDCl3  
NS 8  
DS 2  
SWH 8012.820 Hz  
FIDRES 0.122266 Hz  
AQ 4.0894966 s  
RG 195.79  
DW 62.400 us  
DE 6.50 us  
TE 518.1 K  
DT 1.0000000 s

===== CHANNEL f1 =====  
NUC1 1H  
P1 12.00


201111-24-HPI-040

8.442  
8.168  
8.148  
7.732  
7.728  
7.710  
7.693  
7.689  
7.466  
7.461  
7.355  
7.350  
7.346  
7.341  
7.332  
7.326  
7.321  
7.312  
7.268  
7.259  
7.239  
7.234

CDCl<sub>3</sub>


1.796  
1.574

Compound 22



TMS

Water






1.00

0.91  
1.02  
1.11  
1.01  
3.13  
1.09

2.89


# Compound 23





NOESY 400M  
20110907-1


Compound 24





Current Data Parameters  
NAME 20110907-1  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date 20110907  
Time 15.34  
INSTRUM spect  
PROBHD 5 mm PABBO BB-  
PULPROG zg30  
TD 65536  
SOLVENT DMSO  
NS 8  
DS 2  
SWH 8012.820  
FIDRES 0.122266  
AQ 4.0894966  
RG 127.33  
EW 62.400  
DS 6.50  
TE 298.3  
D1 1.0000000



==== CHANNEL f1 ====  
NUC1 1H  
P1 15.00  
PLW1 12.0000000  
SFO1 400.1326008




# Compound 25



# Compound 26





MPI-013

13.421


NOESY 400M  
20111028-1

Compound 27

8.798  
8.282  
8.217  
8.197  
8.020  
7.999  
7.770  
7.766  
7.728  
7.710  
7.690  
7.614  
7.594  
7.576  
7.556  
7.552  
7.538  
7.518

3.359


2.491





Current Data Parameters  
NAME 20111028  
EXPNO  
PROCNO

F2 - Acquisition Parameters  
Date\_ 201110  
Time\_ 13.  
INSTRUM spect  
PROBHD 5 mm PABBO I  
PULPROG zg  
TD 655  
SOLVENT DMSO  
NS  
DS  
SWH 8012.8  
FIDRES 0.1227  
AQ 4.09948  
RG 195.  
DW 62.4  
DE 6.  
TE 29.  
D1 1.000000

===== CHANNEL f1 =====



Compound 28



20120503-HPI-077

Current Data Parameters  
 NAME 20120503-HPI-077  
 EXPNO 1  
 PROCNO 1

7.930  
 7.494  
 7.390  
 7.367  
 7.275  
 7.120


2.904


1.877  
 1.576  
 1.270

F2 - Acquisition Parameters  
 Date\_ 20120503  
 Time 9.05  
 INSTRUM spect  
 PROBHD 5 mm PABBO BB-  
 PULPROG zg30  
 TD 65536  
 SOLVENT CDCl3  
 NS 8  
 DS 2  
 SWH 8012.820 Hz  
 FIDRES 0.122266 Hz  
 AQ 4.0894966 sec  
 RG 195.79  
 DW 62.400 usec  
 DE 6.50 usec  
 TE 299.4 K  
 D1 1.00000000 sec

----- CHANNEL f1 -----  
 NUC1 1H  
 P1 15.00 usec  
 PLW1 12.00000000 W  
 SFO1 400.1326008 MHz

F2 - Processing parameters  
 SI 65536  
 SF 400.1300037 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00





Current Data Parameters  
 NAME 20120505-HPI-076  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20120504  
 Time 11.03  
 INSTRUM spect  
 PROBHD 5 mm PABBO BB-  
 PULPROG zg30  
 TD 65536  
 SOLVENT DMSO  
 NS 8  
 DS 2  
 SWH 8012.820 Hz  
 FIDRES 0.122266 Hz  
 AQ 4.0894966 sec  
 RG 175.2  
 DW 62.400 usec  
 DE 6.50 usec  
 TE 300.6 K  
 D1 1.00000000 sec

----- CHANNEL f1 -----  
 NUC1 1H  
 P1 15.00 usec  
 PLW1 12.00000000 W  
 SFO1 400.1326008 MHz

F2 - Processing parameters  
 SI 65536  
 SF 400.1300037 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00



20120505-HPI-076

7.746  
7.741  
7.556  
7.552  
7.536  
7.531  
7.507  
7.487  
7.434  
7.346



4.405  
4.398  
4.340  
4.333

Water 3.330  
DMSO 2.504  
2.500  
2.496

Compound 29




Compound 30




20130413-HPI-92


Compound 31



NAME 20130413-HPI-92  
EXPNO 21  
PROCNO 1  
Date\_ 20130412  
Time\_ 14.46  
INSTRUM spect  
PROBHD 5 mm PADUL 13C  
PULPROG zg  
TD 65536  
SOLVENT DMSO  
NS 8  
DS 0  
SWH 5995.204 Hz  
FIDRES 0.091480 Hz  
AQ 5.4657526 sec  
RG 256  
DW 83.400 usec  
DE 6.50 usec  
TE 291.5 K  
D1 2.00000000 sec  
TD0 1


===== CHANNEL f1 =====  
NUC1 1H  
P1 11.25 usec  
PL1 0.00 dB  
PL1W 8.31434441 W  
SFO1 300.1318458 MHz  
SI 32768  
SF 300.1300000 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00





20131111-HPI-104

Compound 32



```

Current Data Parameters
NAME      20131111-HPI-104
EXPNO    1
PROCNO   1

F2 - Acquisition Parameters
Date_    20131107
Time     14.09
INSTRUM  spect
PROBHD   5 mm PABBO BB-
PULPROG  zg30
TD       65536
SOLVENT  DMSO
NS       8
DS       2
SMBR     8012.820 Hz
FIDRES   0.122266 Hz
AQ       4.0894966 sec
RG       195.79
DW       62.400 usec
DE       6.50 usec
TE       299.8 K
DI       1.00000000 sec

----- CHANNEL f1 -----
NUC1     1H
P1       15.00 usec
PLM1     12.00000000 W
SFO1     400.1326008 MHz


F2 - Processing parameters
SI       65536
SF       400.1300037 MHz
WDW      EM
SSB      0
LB       0.30 Hz
GB       0
PC       1.00
  
```

8.005  
7.990  
7.758  
7.637  
7.542  
7.522  
7.430  
7.159


5.296

3.358

2.497



Compound 33



Current Data Parameters  
 NAME 20131107-HPI-105  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date 20131106  
 Time 15.19  
 INSTRUM spect  
 PROBHD 5 mm PABBO BB-  
 PULPROG zg30  
 TD 65536  
 SOLVENT DMSO  
 NS 8  
 DS 2  
 SWH 8012.820 Hz  
 FIDRES 0.122266 Hz  
 AQ 4.0894966 sec  
 RG 195.79  
 DW 62.400 usec  
 DE 6.50 usec  
 TE 299.4 K  
 D1 1.00000000 sec

----- CHANNEL f1 -----  
 NUC1 1H  
 P1 15.00 usec  
 PLW1 12.00000000 W  
 SFO1 400.1326008 MHz

F2 - Processing parameters  
 SI 65536  
 SF 400.1300037 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00


20131107-HPI-105

7.999  
 7.977  
 7.762  
 7.758  
 7.565  
 7.548  
 7.544  
 7.523  
 7.502  
 7.476  
 7.454  
 7.148  
 7.143  
 7.126  
 7.121

5.261

3.373


2.501




DMSO

Water

TMS



Compound 34




20131109-HPI-106



5.238

3.397

2.498





Current Data Parameters  
 NAME 20131109-HPI-106  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20131107  
 Time 14.03  
 INSTRUM spect  
 PROBHD 5 mm PABBO BB-  
 PULPROG zg30  
 TD 65536  
 SOLVENT DMSO  
 NS 8  
 DS 2  
 SMI 8012.820 Hz  
 FIDRES 0.122266 Hz  
 AQ 4.0854566 sec  
 RG 195.79  
 DM 62.400 usec  
 DE 6.50 usec  
 TE 299.9 K  
 DL 1.0000000 sec

----- CHANNEL f1 -----  
 NUCL1 1H  
 P1 15.00 usec  
 PLW1 12.00000000 W  
 SFO1 400.1326008 MHz


F2 - Processing parameters  
 SI 65536  
 SF 400.1300037 MHz  
 MDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00





20131111-HPI-110

Compound 35



Current Data Parameters  
 NAME 20131111-HPI-110  
 EXPNO 1  
 PROCNO 1


F2 - Acquisition Parameters  
 Date\_ 20131119  
 Time 9.33  
 INSTRUM spect  
 PROBHD 5 mm PABBO BS-  
 PULPROG zg30  
 TD 65536  
 SOLVENT DMSO  
 NS 8  
 DS 2  
 SMH 8012.820 Hz  
 FIDRES 0.122266 Hz  
 AQ 4.0894966 sec  
 RG 175.2  
 DW 62.400 usec  
 DE 6.50 usec  
 TE 297.0 K  
 D1 1.00000000 sec


----- CHANNEL f1 -----  
 NUC1 1H  
 P1 15.00 usec  
 PLW1 12.00000000 W  
 SF01 400.1326008 MHz

F2 - Processing parameters  
 SI 65536  
 SF 400.1300037 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00

8.000  
 7.978  
 7.765  
 7.761  
 7.571  
 7.566  
 7.550  
 7.545  
 7.526  
 7.506  
 7.453  
 7.435  
 7.308  
 7.305  
 7.289  
 7.287  
 7.273  
 7.270  
 7.266  
 7.251  
 7.245  
 7.233  
 7.227  
 7.215  
 7.210  
 7.154  
 7.149  
 7.132  
 7.127  
 5.225

3.360  
 2.508  
 2.504  
 2.500  
 2.495  
 2.491  
 2.342








HPI-111



Compound 36





Current Data Parameters  
 NAME 20131111-HPI-112  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20131115  
 Time 15.03  
 INSTRUM spect  
 FROSHD 5 mm PABBO BB-  
 PULPROG zg30  
 TD 65536  
 SOLVENT DMSO  
 NS 8  
 DS 2  
 SWH 8012.820 Hz  
 FIDRES 0.122266 Hz  
 AQ 4.0894966 sec  
 RG 195.79  
 DW 62.400 usec  
 DE 6.50 usec  
 TE 299.2 K  
 D1 1.0000000 sec

===== CHANNEL f1 =====  
 NUC1 1H  
 P1 15.00 usec  
 PLW1 12.00000000 W  
 SFO1 400.1326008 MHz

F2 - Processing parameters  
 SI 65536  
 SF 400.1300037 MHz  
 MW 2M  
 SSB 0  
 LB 0 0.30 Hz  
 GB 0  
 PC 1.00

20131111-HPI-112



7.980  
 7.958  
 7.762  
 7.757  
 7.569  
 7.564  
 7.548  
 7.543  
 7.522  
 7.501  
 7.476  
 7.472  
 7.380  
 7.360  
 7.237  
 7.217  
 7.117  
 7.111  
 7.095  
 7.089

5.187

3.361


2.505  
 2.500  
 2.496  
 2.316

Compound 37



20131127-HPI-107

Compound 38



NAME 20131127-HPI-107  
EXPNO 21  
PROCNO 1  
Date\_ 20131211  
Time 16.47  
INSTRUM spect  
PROBHD 5 mm PADUL 13C  
PULPROG zg  
TD 65536  
SOLVENT DMSO  
MS 8  
DS 0  
SWH 5995.204 Hz  
FIDRES 0.091480 Hz  
AQ 5.4657526 sec  
RG 181  
DW 83.400 usec  
DE 6.50 usec  
TE 293.6 K  
D1 2.0000000 sec  
TDO 1

----- CHANNEL f1 -----  
NUC1 1H  
P1 11.25 usec  
PL1 0.00 dB  
PL1W 8.31434441 W  
SFO1 300.1318458 MHz  
SI 32768  
SF 300.1300000 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
FC 1.00

—13.369

7.991  
7.962  
7.773  
7.548  
7.530  
7.509  
7.443  
7.421  
7.376  
7.129  
7.101  
6.997

—5.186


—3.837

—3.398

—2.889

—2.729

—2.502




0.866

1.279  
0.954  
5.217  
3.216

2.000

3.311



Compound 39



Current Data Parameters  
 NAME 20131111-HPI-108  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20131119  
 Time 9.21  
 INSTRUM spect  
 PROBHD 5 mm PABBO BB-  
 PULPROG zg30  
 TD 65536  
 SOLVENT DMSO  
 NS 8  
 DS 2  
 SWH 8012.820 Hz  
 FIDRES 0.122266 Hz  
 AQ 4.0894966 sec  
 RG 78.8  
 DM 62.400 usec  
 DE 6.50 usec  
 TE 297.0 K  
 D1 1.0000000 sec

----- CHANNEL f1 -----  
 NUC1 1H  
 P1 15.00 usec  
 PL1 12.0000000 W  
 SFO1 400.1326008 MHz


F2 - Processing parameters  
 SI 65536  
 SF 400.1300037 MHz  
 MCW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00

20131111-HPI-108  
 7.984  
 7.962  
 7.753  
 7.639  
 7.520  
 7.497  
 7.466  
 7.346  
 7.332  
 7.313  
 7.125  
 7.105  
 7.042  
 6.934

5.204  
 3.762  
 3.759  
 3.411  
 2.498

Water

DMSO




0.74

1.00  
 0.91  
 2.77  
 0.96  
 2.83  
 0.81

1.96

3.23



20131111-HPI-109

Compound 40

Current Data Parameters  
 NAME 20131111-HPI-109  
 EXPNO 1  
 PROCNO 1  
 F2 - Acquisition Parameters  
 Date\_ 20131119  
 Time 9.28  
 INSTRUM spect  
 FREQSHD 5 == PASSED HB-  
 FULPROG zg30  
 TD 65536  
 SOLVENT DMSO  
 NS 8  
 DS 2  
 SWH 8012.820 Hz  
 FIDRES 0.122266 Hz  
 AQ 4.0894966 sec  
 RG 175.2  
 DW 62.400 usec  
 DE 6.50 usec  
 TE 297.0 K  
 D1 1.00000000 sec  
 ----- CHANNEL f1 -----  
 NUC1 1H  
 P1 15.00 usec  
 PLW1 12.00000000 W  
 SFO1 400.1326008 MHz  
 F2 - Processing parameters  
 SI 65536  
 SF 400.1300037 MHz  
 WMW EM  
 SSS 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00


7.965  
7.943  
7.747  
7.557  
7.537  
7.533  
7.511  
7.491  
7.431  
7.410  
7.077  
7.055  
6.983  
6.961

5.146


Water


DMSO

2.504  
2.500  
2.496






TMS







20131119-HPI-116

Compound 41





20131111-HPI-117



Current Data Parameters  
 NAME 20131111-HPI-117  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20131119  
 Time 9.43  
 INSTRUM spect  
 PROBHD 5 mm PABBO BB-  
 PULPROG zg30  
 TD 65536  
 SOLVENT DMSO  
 NS 8  
 DS 2  
 SWH 8012.820 Hz  
 FIDRES 0.122266 Hz  
 AQ 4.0894966 sec  
 RG 175.2  
 DW 62.400 usec  
 DE 6.50 usec  
 TE 297.1 K  
 D1 1.0000000 sec


----- CHANNEL f1 -----  
 NUC1 1H  
 P1 15.00 usec  
 PL1 12.0000000 W  
 SFO1 400.1326008 MHz

F2 - Processing parameters  
 SI 65536  
 SF 400.1300037 MHz  
 WDM EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00

8.004  
 7.982  
 7.973  
 7.866  
 7.848  
 7.829  
 7.765  
 7.761  
 7.673  
 7.654  
 7.635  
 7.570  
 7.566  
 7.549  
 7.545  
 7.523  
 7.502  
 7.484  
 7.158  
 7.153  
 7.136  
 7.130  
 5.305


3.372

2.500





NAME 20131125-HPI-118  
 EXPNO 21  
 PROCNO 1  
 Date\_ 20131125  
 Time\_ 19.42  
 INSTRUM spect  
 PROBHD 5 mm PADUL 13C  
 PULPROG zg  
 TD 65536  
 SOLVENT DMSO  
 NS 8  
 DS 0  
 SWH 5995.204 Hz  
 FIDRES 0.091480 Hz  
 AQ 5.4657526 sec  
 RG 128  
 DW 83.400 usec  
 DE 6.50 usec  
 TE 293.7 K  
 D1 2.00000000 sec  
 TDO 1


===== CHANNEL f1 =====  
 NUC1 1H  
 P1 11.25 usec  
 PL1 0.00 dB  
 PL1W 8.31434441 W  
 SFO1 300.1318458 MHz  
 SI 32768  
 SF 300.1300000 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00



20131125-HPI-118  
 8.001  
 7.972  
 7.922  
 7.896  
 7.763  
 7.686  
 7.661  
 7.540  
 7.524  
 7.474  
 7.152  
 7.124  
 — 5.354  
 — 3.405  
 — 2.502  
 — 1.225  
 — 0.846  
 — 0.825




Compound 43







20131107-HPI-113

Compound 44





Compound 45



20131202-HPI-114

13.576  
13.507  
13.482  
13.454  
13.322  
13.253  
13.223

8.762  
8.629  
8.618  
8.011  
7.995  
7.973  
7.751  
7.554  
7.539  
7.512  
7.492  
7.447  
7.126  
7.105

5.313

3.365

2.500

1.232


0.002

Current Data Parameters  
NAME 20131202-HPI-114  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date 20131202  
Time 16.32  
INSTRUM spect  
PROBHD 5 mm PABBO BB-  
PULPROG zg30  
TD 65536  
SOLVENT DMSO  
NS 8  
DS 2  
SWH 8012.820 Hz  
FIDRES 0.122266 Hz  
AQ 4.0894966 sec  
RG 195.79  
DW 62.400 usec  
DE 6.50 usec  
TE 296.5 K  
D1 1.00000000 sec



==== CHANNEL f1 =====  
NUC1 1H  
P1 15.00 usec  
PLW1 12.00000000 W  
SFO1 400.1326008 MHz

F2 - Processing parameters  
SI 65536  
SF 400.1300037 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00




20131107-HPI-115

Compound 46




8.656  
8.645  
7.978  
7.956  
7.710  
7.556  
7.543  
7.524  
7.503  
7.476  
7.455  
7.247  
7.080  
7.059  
5.372



20131126-HPI-121

Compound 47

13.651  
13.509  
13.371  
13.331  
13.322  
13.210  
13.204  
13.144




7.968  
7.757  
7.537  
7.466  
7.056  
6.966

6.028

5.110

3.371




Current Data Parameters  
NAME 20131126-HPI-121  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20131126  
Time 14.56  
INSTRUM spect  
PROBHD 5 mm PABBO BB-  
PULPROG zg30  
TD 65536  
SOLVENT DMSO  
NS 8  
DS 2  
SWH 8012.820 Hz  
FIDRES 0.122266 Hz  
AQ 4.0894966 sec  
RG 175.2  
DW 62.400 usec  
DE 6.50 usec  
TE 297.3 K  
D1 1.00000000 sec

----- CHANNEL f1 -----  
NUC1 1H  
P1 15.00 usec  
PLW1 12.00000000 W  
SFO1 400.1326008 MHz

F2 - Processing parameters  
SI 65536  
SF 400.1300037 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00



20131126-HPI-122

Compound 48

